NCT03046251View on ClinicalTrials.gov

Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Multiple Sclerosis
Interventions
DRUG

Natalizumab

Trial Locations (1)

14203

SUNY Buffalo, Buffalo

All Listed Sponsors
lead

State University of New York at Buffalo

OTHER

NCT03046251 - Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis | Biotech Hunter | Biotech Hunter